We found that the expression levels of IDH2 were negatively correlated with overall survival (OS) in lung cancer patients treated with chemotherapy (p = 0.009), but not in lung cancer patients who did not undergo chemotherapy (Figure 1A,B), suggesting that IDH2 could potentially affect drug sensitivity. Here, IDH2 is linked to lung carcinoma.